28066805|t|Evaluation of Soft Tissue Sarcoma Response to Preoperative Chemoradiotherapy Using Dynamic Contrast-Enhanced Magnetic Resonance Imaging
28066805|a|This study aims to assess the utility of quantitative dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) parameters in comparison with imaging tumor size for early prediction and evaluation of soft tissue sarcoma response to preoperative chemoradiotherapy. In total, 20 patients with intermediate- to high-grade soft tissue sarcomas received either a phase I trial regimen of sorafenib + chemoradiotherapy (n = 8) or chemoradiotherapy only (n = 12), and underwent DCE-MRI at baseline, after 2 weeks of treatment with sorafenib or after the first chemotherapy cycle, and after therapy completion. MRI tumor size in the longest diameter (LD) was measured according to the RECIST (Response Evaluation Criteria In Solid Tumors) guidelines. Pharmacokinetic analyses of DCE-MRI data were performed using the Shutter-Speed model. After only 2 weeks of treatment with sorafenib or after 1 chemotherapy cycle, K(trans) (rate constant for plasma / interstitium contrast agent transfer) and its percent change were good early predictors of optimal versus suboptimal pathological response with univariate logistic regression C statistics values of 0.90 and 0.80, respectively, whereas RECIST LD percent change was only a fair predictor (C = 0.72). Post-therapy K(trans), ve (extravascular and extracellular volume fraction), and kep (intravasation rate constant), not RECIST LD, were excellent (C > 0.90) markers of therapy response. Several DCE-MRI parameters before, during, and after therapy showed significant (P < .05) correlations with percent necrosis of resected tumor specimens. In conclusion, absolute values and percent changes of quantitative DCE-MRI parameters provide better early prediction and evaluation of the pathological response of soft tissue sarcoma to preoperative chemoradiotherapy than the conventional measurement of imaging tumor size change.
28066805	0	10	Evaluation	T058	C0220825
28066805	14	33	Soft Tissue Sarcoma	T191	C0039101
28066805	34	42	Response	T033	C1704632
28066805	46	58	Preoperative	T079	C0445204
28066805	59	76	Chemoradiotherapy	T061	C0436307
28066805	83	135	Dynamic Contrast-Enhanced Magnetic Resonance Imaging	T060	C1831914
28066805	141	146	study	T062	C2603343
28066805	155	161	assess	T058	C0184514
28066805	166	173	utility	T169	C0457083
28066805	177	254	quantitative dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI)	T060	C1831914
28066805	255	265	parameters	T077	C0549193
28066805	269	279	comparison	T052	C1707455
28066805	285	292	imaging	T060	C0011923
28066805	293	303	tumor size	T082	C0475440
28066805	308	324	early prediction	T078	C0681842
28066805	329	339	evaluation	T058	C0220825
28066805	343	371	soft tissue sarcoma response	T040	C1817727
28066805	375	387	preoperative	T079	C0445204
28066805	388	405	chemoradiotherapy	T061	C0436307
28066805	420	428	patients	T101	C0030705
28066805	462	482	soft tissue sarcomas	T191	C0039101
28066805	501	514	phase I trial	T062	C0920321
28066805	515	522	regimen	T061	C0040808
28066805	526	535	sorafenib	T109,T121	C1516119
28066805	538	555	chemoradiotherapy	T061	C0436307
28066805	567	589	chemoradiotherapy only	T061	C0436307
28066805	614	621	DCE-MRI	T060	C1831914
28066805	625	633	baseline	T081	C1442488
28066805	643	648	weeks	T079	C0439230
28066805	652	661	treatment	T061	C0087111
28066805	667	676	sorafenib	T109,T121	C1516119
28066805	690	714	first chemotherapy cycle	T061	C1302181
28066805	726	733	therapy	T061	C0087111
28066805	734	744	completion	T080	C0205197
28066805	746	749	MRI	T060	C0024485
28066805	750	760	tumor size	T082	C0475440
28066805	768	784	longest diameter	T081	C0552406
28066805	786	788	LD	T081	C0552406
28066805	794	802	measured	T080	C0444706
28066805	820	826	RECIST	T170	C1709926
28066805	828	872	Response Evaluation Criteria In Solid Tumors	T170	C1709926
28066805	874	884	guidelines	T170	C0162791
28066805	886	910	Pharmacokinetic analyses	T062	C0201734
28066805	914	921	DCE-MRI	T060	C1831914
28066805	922	926	data	T078	C1511726
28066805	932	941	performed	T169	C0884358
28066805	952	971	Shutter-Speed model	T170	C3161035
28066805	986	991	weeks	T079	C0439230
28066805	995	1004	treatment	T061	C0087111
28066805	1010	1019	sorafenib	T109,T121	C1516119
28066805	1031	1049	chemotherapy cycle	T061	C1302181
28066805	1051	1059	K(trans)	T081	C2825157
28066805	1061	1074	rate constant	T081	C2825157
28066805	1079	1085	plasma	T031	C0032105
28066805	1088	1100	interstitium	T023	C2328510
28066805	1101	1124	contrast agent transfer	T062	C2985649
28066805	1134	1148	percent change	T081	C3272907
28066805	1159	1175	early predictors	T078	C2698872
28066805	1205	1226	pathological response	T033	C4050242
28066805	1232	1282	univariate logistic regression C statistics values	UnknownType	C0681925
28066805	1323	1329	RECIST	T170	C1709926
28066805	1330	1332	LD	T081	C0552406
28066805	1333	1347	percent change	T081	C3272907
28066805	1359	1373	fair predictor	T078	C2698872
28066805	1386	1398	Post-therapy	T079	C1882428
28066805	1399	1407	K(trans)	T081	C2825157
28066805	1409	1411	ve	T081	C0560268
28066805	1413	1426	extravascular	T026	C0243092
28066805	1431	1444	extracellular	T026	C0521119
28066805	1445	1460	volume fraction	T081	C0560268
28066805	1467	1470	kep	T081	C2986811
28066805	1472	1499	intravasation rate constant	T081	C2986811
28066805	1506	1512	RECIST	T170	C1709926
28066805	1513	1515	LD	T081	C0552406
28066805	1522	1531	excellent	T080	C1961136
28066805	1554	1570	therapy response	T169	C1514305
28066805	1580	1587	DCE-MRI	T060	C1831914
28066805	1588	1598	parameters	T077	C0549193
28066805	1599	1605	before	T079	C0332152
28066805	1607	1613	during	T079	C0347984
28066805	1619	1624	after	T079	C1548614
28066805	1625	1632	therapy	T061	C0087111
28066805	1662	1674	correlations	T081	C0010100
28066805	1680	1696	percent necrosis	T033	C1334928
28066805	1700	1708	resected	T080	C1521996
28066805	1709	1714	tumor	T191	C0027651
28066805	1715	1724	specimens	T167	C0370003
28066805	1741	1749	absolute	T080	C0205344
28066805	1750	1756	values	T080	C0042295
28066805	1761	1776	percent changes	T081	C3272907
28066805	1780	1792	quantitative	T081	C0392762
28066805	1793	1800	DCE-MRI	T060	C1831914
28066805	1801	1811	parameters	T077	C0549193
28066805	1820	1826	better	T033	C4036142
28066805	1827	1843	early prediction	T078	C0681842
28066805	1848	1858	evaluation	T058	C0220825
28066805	1866	1887	pathological response	T033	C4050242
28066805	1891	1910	soft tissue sarcoma	T191	C0039101
28066805	1914	1926	preoperative	T079	C0445204
28066805	1927	1944	chemoradiotherapy	T061	C0436307
28066805	1954	1978	conventional measurement	T080	C0444706
28066805	1982	1989	imaging	T060	C0011923
28066805	1990	1995	tumor	T191	C0027651
28066805	1996	2007	size change	T081	C0541591